Answers are grounded in this paper and cite their sources.
INTRODUCTION: The Varian Ethos adaptive radiotherapy system was upgraded from version 1.0 to 2.0, introducing an enhanced multi-leaf collimator (MLC) dose calculation model and a new optimization engine. We evaluated whether this affected agreement between calculated and measured dose, and plan complexity. MATERIAL AND METHODS: Twenty-four plans (14 intensity-modulated radiotherapy [IMRT], 10 volumetric modulated arc therapy [VMAT]; 26 measurement configurations) covering 10 anatomical sites were analyzed in three matched configurations: original Ethos 1.0 plans (E1.0), the same plans recalculated in Ethos 2.0 with the new MLC model only (E1.0→2.0), and plans re-optimized in Ethos 2.0 (E2.0). Quality assurance comprised ionization chamber point-dose measurement and global gamma analysis on an ArcCHECK array at 3%/3 mm, 3%/2 mm and 2%/2 mm (10% threshold). Complexity was quantified with UCoMX v1.1; groups were compared with the Wilcoxon signed-rank test. RESULTS: Mean signed chamber deviation was -1.59 ± 0.54% (E1.0), -1.54 ± 0.57% (E1.0→2.0) and -1.39 ± 0.63% (E2.0), with no significant differences (p > 0.6); all met the ±3% criterion. Gamma pass rates at 3%/3 mm were 99.2 ± 0.9%, 98.7 ± 1.0% (p < 0.001) and 98.6 ± 2.1% (p = 0.059). Re-optimized plans used 12% fewer monitor units (1,169 ± 395 vs. 1,338 ± 471, p < 0.001) and were simpler (MCSv 0.31 to 0.35; SAS10 mm 0.27 to 0.20; both p < 0.001). CONCLUSION: The upgrade preserved quality-assurance compliance and produced simpler, lower--monitor-unit plans, but the systematic -1.5% offset between calculated and measured point dose persisted, showing the new MLC model alone does not remove it.
No takes yet. Share an insight, caveat, or question.
Wesolowska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: